Nicole Fleming, MD
Gynecologic Oncology · Seattle, WANPI 1881890796
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $16,375 of the $19,570 with a category attached, or 83.7%. 17 manufacturers reported payments, led by Tesaro, Inc. at 38.7% of the total. Reporting peaked in 2019 at $13,647 and has fallen 99.9% since, to $18 in 2025. Among gynecologic oncology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 50 payments — averaging $391.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tesaro, Inc.$8K
- E.r. Squibb & Sons, L.L.C.$6K
- GSK$5K
- Genentech USA, Inc.$261
- Clovis Oncology, Inc.$182
- Eisai Inc.$177
- plus $587 from 11 others
Across 23 payments — averaging $5052.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Clovis Oncology, Inc.$116K
What the payments were for
- Consulting fees$16,37584%
- Travel & lodging$1,3397%
- Food & beverage$1,6809%
- Education$1771%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tesaro, Inc. | 8 | $7,567 |
| E.r. Squibb & Sons, L.L.C. | 10 | $5,725 |
| GSK | 3 | $5,071 |
| Genentech USA, Inc. | 3 | $261 |
| Clovis Oncology, Inc. | 2 | $182 |
| Eisai Inc. | 3 | $177 |
| Bristol Myers Squibb | 1 | $125 |
| Gilead | 4 | $81 |
| Nestle Healthcare Nutrition Inc. | 3 | $72 |
| Immunogen, Inc. | 1 | $63 |
| Hologic Sales And Service, LLC | 2 | $51 |
| Ferring Pharmaceuticals Inc. | 2 | $45 |
| Mayne Pharma Commercial LLC | 2 | $42 |
| Johnson & Johnson | 2 | $39 |
| Agile Therapeutics, Inc. | 2 | $26 |
| EMD Serono, Inc. | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,570 in reported general payments places this provider in the 90th percentile of 36 gynecologic oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 17 | $116 |
| Ondansetron Hcl | 13 | $114 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Seattle
- Chirag ShahSeattle$732K
- Fernanda MusaSeattle$120K
- Bobbie RimelSeattle$41K
- Renata UrbanSeattle$7K
- Amy BrockmeyerSeattle$4K
- Amy BondurantSeattle$2K
- Kathryn PenningtonSeattle$2K
- Soledad JorgeSeattle$1K
- Elise SimonsSeattle$459
- Allison BarrieSeattle$428
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.